Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Helical nanoplatelet superlattices assembled from green emissive CsPbI<sub>3</sub> nanoplatelets.

Chemical communications (Cambridge, England)·2026
Same author

One-dimensional CsPbBr<sub>3</sub> superlattices with polarized and amplified spontaneous circularly polarized emissions.

Nature communications·2026
Same author

Cardiac α4β2 nicotinic receptors as a therapeutic target for fatal ventricular arrhythmias.

European heart journal·2026
Same author

A chromosome-level genome assembly of the Tristram's Bunting (Emberiza tristrami).

Scientific data·2026
Same author

Seasonal variation in activity rhythms of leopard cats (Prionailurus bengalensis), their prey and competitors in southern Anhui.

Scientific reports·2026
Same author

Navigating the trade-off: Thermal hydrolysis as a winning pretreatment for simultaneously enhancing methanogenesis and immobilizing cadmium in waste activated sludge.

Journal of hazardous materials·2026

Related Experiment Video

Updated: May 7, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.2K

Varenicline and Ventricular Ectopy After Myocardial Infarction: A Randomized Phase 2 Study.

Yunli Shen1, Xiaogang Guo2, Chunyu Zeng3

  • 1State Key Laboratory of Cardiovascular Diseases, Department of Cardiology, and Shanghai Arrhythmia Research Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.

Journal of the American College of Cardiology
|March 4, 2026
PubMed
Summary

Varenicline significantly reduced premature ventricular complexes (PVCs) and ventricular tachycardia in post-MI patients. This novel approach targeting cardiac nicotinic acetylcholine receptors (nAChRs) shows promise as a safe antiarrhythmic therapy.

Keywords:
antiarrhythmic therapymyocardial infarctionnicotinic acetylcholine receptorsphase 2 clinical trialpremature ventricular complexesvarenicline

More Related Videos

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
06:57

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction

Published on: January 31, 2019

15.4K
A Model of Long-Term Ventricular Fibrillation in Isolated Rat Hearts
07:56

A Model of Long-Term Ventricular Fibrillation in Isolated Rat Hearts

Published on: February 17, 2023

1.4K

Related Experiment Videos

Last Updated: May 7, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.2K
Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
06:57

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction

Published on: January 31, 2019

15.4K
A Model of Long-Term Ventricular Fibrillation in Isolated Rat Hearts
07:56

A Model of Long-Term Ventricular Fibrillation in Isolated Rat Hearts

Published on: February 17, 2023

1.4K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Conventional antiarrhythmic drugs pose proarrhythmic risks.
  • Cardiac nicotinic acetylcholine receptors (nAChRs) offer a novel therapeutic target.

Purpose of the Study:

  • To evaluate varenicline's efficacy and safety in reducing premature ventricular complexes (PVCs) post-myocardial infarction (MI).
  • To assess varenicline's biological target engagement and antiarrhythmic potential.

Main Methods:

  • A multicenter, randomized, double-blind, placebo-controlled phase 2 trial.
  • 118 adults with frequent PVCs post-MI received varenicline or placebo for 45 days.
  • Primary endpoint: percentage change in 24-hour PVC count; secondary endpoints: responder rate and nonsustained ventricular tachycardia (VT) incidence.

Main Results:

  • Varenicline significantly reduced PVC burden by 60.1% compared to placebo (P = 0.001).
  • Higher responder rates (67.8% vs 30.5%) and lower nonsustained VT incidence (20.3% vs 37.3%) were observed with varenicline.
  • Adverse event rates were comparable, with no deaths or malignant ventricular arrhythmias in the varenicline group.

Conclusions:

  • Varenicline effectively reduces PVC burden and VT incidence in post-MI patients without proarrhythmic effects.
  • Cardiac nAChRs are a viable antiarrhythmic target.
  • Further large-scale outcome trials are warranted to confirm these findings.